BSE filing, NSE: ASTRAZEN. Summary written from the filing by ALFA Finder's alert engine.
AstraZeneca Pharma India Ltd: key numbers
- Share price
- ₹6,279.50
- Market cap
- ₹15,699 Cr
- Revenue (annual)
- ₹2,276 Cr
- Net profit (annual)
- ₹187.5 Cr
- P/E (TTM)
- 92.5×Sector 46.1×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 2.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from AstraZeneca Pharma India Ltd
All →AstraZeneca Pharma India Capacity Expansion
AstraZeneca Pharma India inaugurated a new corporate office in Mumbai, covering 25,600 sq ft. This expansion strengthens the company's commercial operations and footprint in India.
- office space
- 25600.0 sq ft
AstraZeneca Pharma India Annual General Meeting
AstraZeneca Pharma India Ltd declared the voting results of its postal ballot, confirming the appointment and designation change of certain non-executive directors.
AstraZeneca Pharma India Other Announcement
NSE Sustainability Ratings and Analytics assigned AstraZeneca Pharma India an ESG rating of 73 for FY 2025-26. The rating was independently prepared without company engagement.
AstraZeneca Pharma India Legal & Regulatory
AstraZeneca Pharma India Limited received an order from the ROC, Bengaluru, imposing a total penalty of ₹0.03 Crore for a delayed filing. The company is evaluating next steps.
- Value
- ₹0.03 Cr
- From
- Registrar of Companies, Bengaluru, Karnataka
AstraZeneca Pharma India Legal & Regulatory
AstraZeneca Pharma disclosed a ₹1.88 lakh penalty from the Registrar of Companies due to a delay in filing Form MR-2.
- Value
- ₹0.02 Cr
AstraZeneca Pharma India Other Announcement
AstraZeneca Pharma India reported receiving an ESG rating of 64 from Crisil ESG Ratings. The assessment was independently prepared using publicly available information.
Other management change announcements
All →EverestIMS Technologies Management Change
EverestIMS discloses that Whole-Time Director Arun Prasath Ramadoss will step down from the executive role. He continues as Non-Executive Non-Independent Director from January 28, 2027.
Laurus Labs Management Change
Laurus Labs appointed Mr. Kundan Kumar Jha as Joint Company Secretary effective November 1, 2026, following Board approval. The KMP appointment advances the company's succession planning process.
Heidelbergcement India Management Change
HeidelbergCement India appointed Anu Mehta as Director-HR effective December 1, 2026. Poonam Sharma retired from the same role effective November 30, 2026.
Equitas Small Finance Bank Management Change
Equitas Small Finance Bank's MD & CEO P. N. Vasudevan resigned effective upon successor appointment. The Board will recommend suitable candidates subject to RBI approval.
Integrated Proteins Management Change
Integrated Proteins appointed Ms. Arushi Aggarwal as Company Secretary and Compliance Officer, effective 29 October 2026. The appointment was approved at a board meeting as a Key Managerial Personnel change.
Suraj Management Change
Suraj Limited appointed Mr. Mayank Balvantbhai Rami as Company Secretary and Compliance Officer effective November 1, 2026. The board approved this KMP appointment on October 29, 2026.